ArticleThe Laryngoscope2013
Fluorescently labeled therapeutic antibodies for detection of microscopic melanoma.
Article in The Laryngoscope, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 39 citations in OpenAlex.
- Effects of an Unlabeled Loading Dose on Tumor-Specific Uptake of a Fluorescently Labeled Antibody for Optical Surgical Navigation.Molecular imaging and biology · 2017Trial
- Characterizing the Utility and Limitations of Repurposing an Open-Field Optical Imaging Device for Fluorescence-Guided Surgery in Head and Neck Cancer Patients.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Trial
- Automated cGMP optical labeling of FDA-approved antibodies for human use.Nature protocols · 2026Review
- Rapid assessment of target-binding fractions in molecular imaging agents using size-exclusion HPLC.EJNMMI radiopharmacy and chemistry · 2026Article
- Open-field fluorescence guided imaging of ameloblastoma tumors in mouse patient-derived xenograft model.BMC oral health · 2026Article
- Porphyrin-lipid nanotheranostics for multimodal imaging of nodal disease in preclinical oral cancers.Theranostics · 2026Article
- Leverage Weakly Annotation to Pixel-wise Annotation via Zero-shot Segment Anything Model for Molecular-empowered Learning.Proceedings of SPIE--the International Society for Optical Engineering · 2024Article
- Democratizing Pathological Image Segmentation with Lay Annotators via Molecular-empowered Learning.Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention · 2023Article
- Article
- Review
- Safety and Stability of Antibody-Dye Conjugate in Optical Molecular Imaging.Molecular imaging and biology · 2021Article
- Fluorescently Labeled Cetuximab-IRDye800 for Guided Surgical Excision of Ameloblastoma: A Proof of Principle Study.Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons · 2020Article
- The Clinical Application of Fluorescence-Guided Surgery in Head and Neck Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- Detection and Differentiation of Breast Cancer Sub-Types using a cPLA2α Activatable Fluorophore.Scientific reports · 2019Article
- Rapid, non-invasive fluorescence margin assessment: Optical specimen mapping in oral squamous cell carcinoma.Oral oncology · 2019Article
- Emerging Fluorescent Molecular Tracers to Guide Intra-Operative Surgical Decision-Making.Frontiers in pharmacology · 2019Review
- Improved Debulking of Peritoneal Tumor Implants by Near-Infrared Fluorescent Nanobody Image Guidance in an Experimental Mouse Model.Molecular imaging and biology · 2018Article
- Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies.The Laryngoscope · 2016Article
- Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery.Molecular imaging and biology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectives/hypothesisDetection of microscopic disease during surgical resection of melanoma remains a significant challenge. To assess real-time optical imaging for visualization of microscopic cancer, we evaluated three US Food and Drug Administration (FDA)-approved therapeutic monoclonal antibodies. STUDY
designProspective, basic science.
methodsMelanoma cell lines (A375 and SKMEL5) were xenografted into the ears of immunodeficient mice. Bevacizumab, panitumumab, tocilizumab, or a nonspecific immunoglobin G (IgG) were covalently linked to a near-infrared (NIR) fluorescent probe (IRDye800CW) and systemically injected. Primary tumors were imaged and then resected under fluorescent guidance using the SPY (Novadaq, Toronto, Ontario, Canada), an NIR imaging system used in plastic and reconstructive surgeries to evaluate perfusion. Mice were also imaged with the Pearl Impulse small animal imager (LI-COR Biosciences, Lincoln, NE), an NIR imaging system designed for use with IRDye800CW. Postresection, small tissue fragments were fluorescently imaged and the presence of tumor subsequently confirmed by correlation with histology.
resultsAll fluorescently labeled therapeutic monoclonal antibodies could adequately delineate tumor from normal tissue based on tumor-to-background ratios (TBR) compared to IgG-IRDye800CW. On serial imaging, panitumumab achieved the highest TBRs with both SPY and Pearl (3.8 and 6.6, respectively). When used to guide resections, the antibody-dye conjugates generated TBRs in the range of 1.3 to 2.2 (average, 1.6) using the SPY and 1.9 to 6.3 (average, 2.7) using the Pearl. There was no significant difference among the antibodies with either imaging modality or cell line (one-way analysis of variance).
conclusionsOur data suggest that FDA-approved antibodies may be suitable targeting agents for the intraoperative fluorescent detection of melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.